Navigation Links
Ortho Organizers(R) Introduces Product Line Extension - Rectangular Super Elastic Nitanium(R) Black Ti(TM) Archwire
Date:12/7/2007

CARLSBAD, Calif., Dec. 7 /PRNewswire/ -- Ortho Organizers, Inc., a leading manufacturer of orthodontic products and continuing education programs, announced today that it has added a rectangular version to its already popular Super Elastic Nitanium Black Ti Archwire product line.

The Super Elastic Nitanium Black Ti Archwire product offering has gained popularity with those practitioners within the orthodontic field placing self-ligating brackets due its ultra smooth, hard oxide surface which provides increased archwire integrity and improved resiliency, while reducing sliding friction. The black oxide treatment will not chip, wear or peel.

With 12 dimensions to choose from, the Rectangular Super Elastic Nitanium Black Ti Archwire provides the practitioner a complete selection to finish their case. A center dimple on the archwire ensures accurate placement at the mid line in upper and lower arches and helps prevent rotation out of buccal tubes.

About the Company

Ortho Organizers provides a wide range of orthodontic products to the worldwide dental market. The Company sells directly to U.S. practitioners and through an established network of independent dealers in International markets. For more information on Ortho Organizers contact us at: 800.547.2000 or 760.448.8600, via email: usasales@orthoorganizers.com or via our Web site at http://www.orthoorganizers.com.

Ortho Organizers, Nitanium and Black Ti are trademarks or registered trademarks of Ortho Organizers, Inc.

This press release contains or may contain forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthodontics industry, management's beliefs and assumptions made by management. Forward-looking statements may be
'/>"/>

SOURCE Ortho Organizers, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
2. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
3. OrthoSynetics(TM) Opens New Data Center, Colocation Facility
4. Bone-growing nanomaterial could improve orthopaedic implants
5. Orthopedic Development Corporations TruFUSE(R) Procedure Tops 1,750 Patients in First Year
6. Design Resource Extends Support for Orthopaedic and Cardiovascular Devices
7. Statement of DePuy Orthopaedics, Inc. Regarding Agreement with U.S. Attorneys Office
8. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
9. Orthofix International Acquires InSWing(TM) Interspinous Process Spacer
10. Stuart Collins Joins OrthoSynetics(TM) as Director, Eastern Region Sales
11. Midwest Orthopaedic Research Foundation Lays Out Global Vision for the Future
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:NutraCea Announces Third Quarter 2008 Financial Results 2Health News:NutraCea Announces Third Quarter 2008 Financial Results 3Health News:NutraCea Announces Third Quarter 2008 Financial Results 4Health News:NutraCea Announces Third Quarter 2008 Financial Results 5Health News:NutraCea Announces Third Quarter 2008 Financial Results 6Health News:NutraCea Announces Third Quarter 2008 Financial Results 7Health News:NutraCea Announces Third Quarter 2008 Financial Results 8Health News:NutraCea Announces Third Quarter 2008 Financial Results 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 14Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 15Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 16Health News:Misys Wins 'Best Trade Processing Product' Accolade in European Banking Technology Readers' Choice Awards 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 3Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 4Health News:More People Living Longer After Cancer Diagnosis 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 3
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Warner Chilcott Announces Secondary Equity Offering 6242 1Warner Chilcott Announces Secondary Equity Offering 6242 2Warner Chilcott Announces Secondary Equity Offering 6242 3Warner Chilcott Announces Secondary Equity Offering 6242 4Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 1Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 2Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 3Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 4Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 1Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 2Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 3Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 4Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 5Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 6Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 7
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 2Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 3